Patient recounts IL‑2 therapy chills, rigors, ICU seizure scare, and recovery—what treatment feels like and why monitoring ...

Every single type of cancer, explained A cancer diagnosis can be both terrifying and confusing for those afflicted, as well ...

Day One Biopharmaceuticals, Inc., now part of Servier Group, today announced that it has completed enrollment in the ...

Investigators analyzed the immune-modulatory cancer vaccine IO102-IO103 plus pembrolizumab for PFS in patients with untreated advanced melanoma.

Treatments based on genomic profiling can significantly extend survival for patients with advanced or rare cancer, but only ...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) Q1 net sales of $106.7 million, ...

Immunocore reports first quarter financial results and provides a business update KIMMTRAK- (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: ...

Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the ...

Despite discontinuing an early-stage program, the firm remains committed to growing through internal programs like Padcev, ...

Clinical trial recruitment is currently ongoing for lung, breast, pancreatic, colorectal, and uterine cancers, the deadliest ...

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug ...

Earnings Driven by Focused Execution and 22% Op Revenue Growth of Launched and Acquired Products(1)Pipeline Momentum Builds on Positive Phase 3 and Mid-Stage ReadoutsRobust Late‑Stage R&D Pipeline, On ...